(Q33560026)

28 July 2017

title

Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity (English)

1 reference

28 July 2017

0 references

Claudio Russo

11

0 references

Michele Tonelli

Michele Tonelli

2

0 references

Alessandro Corsaro

Alessandro Corsaro

4

0 references

Stefano Thellung

Stefano Thellung

3

0 references

Anna Sparatore

Anna Sparatore

12

0 references

Tullio Florio

Tullio Florio

16

0 references

author name string

Valentina Villa

1

1 reference

28 July 2017

Bruno Tasso

5

1 reference

28 July 2017

Federica Novelli

6

1 reference

28 July 2017

Caterina Canu

7

1 reference

28 July 2017

Albiana Pino

8

1 reference

28 July 2017

Katia Chiovitti

9

1 reference

28 July 2017

Domenico Paludi

10

1 reference

28 July 2017

Antonio Aceto

13

1 reference

28 July 2017

Vito Boido

14

1 reference

28 July 2017

Fabio Sparatore

15

1 reference

28 July 2017

publication date

20 April 2010

1 reference

28 July 2017

published in

Neurotoxicity Research

1 reference

28 July 2017

volume

19

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

556-574

1 reference

https://scigraph.springernature.com/pub.10.1007/s12640-010-9189-8

28 July 2017

exact match

0 references

cites work

Mammalian prion biology: one century of evolving concepts

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Evaluation of quinacrine treatment for prion diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Combined quinacrine and chlorpromazine therapy in fatal familial insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

The anti-prion activity of Congo red. Putative mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Interactions between prion protein isoforms: the kiss of death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Potent inhibition of scrapie-associated PrP accumulation by congo red

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Synthesis and antiinflammatory evaluation of 9-anilinoacridine and 9-phenoxyacridine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Expression in E. coli and purification of recombinant fragments of wild type and mutant human prion protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Prion protein fragment 106-126 induces a p38 MAP kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid fibril formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

The efficacy of tetracyclines in peripheral and intracerebral prion infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Tetracyclines affect prion infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Clinical trials for prion disease: difficult challenges, but hope for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Continuous quinacrine treatment results in the formation of drug-resistant prions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Emerging pharmacotherapies for Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation. Role of Bcl-2 protein family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Potent inhibition of scrapie prion replication in cultured cells by bis-acridines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Results of quinacrine administration to patients with Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Antiprion activity of functionalized 9-aminoacridines related to quinacrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Prion protein fragment PrP-(106-126) induces apoptosis via mitochondrial disruption in human neuronal SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Porphyrin and phthalocyanine antiscrapie compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Molecular biology of prion diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Shattuck lecture--neurodegenerative diseases and prions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Therapeutic approaches to prion diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

In vitro and in vivo neurotoxicity of prion protein oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

4-Aminoquinoline quinolizidinyl- and quinolizidinylalkyl-derivatives with antimalarial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Systematic review of therapeutic interventions in human prion disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

p38 MAP kinase mediates the cell death induced by PrP106-126 in the SH-SY5Y neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

A systematic review of prion therapeutics in experimental models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Characterization of the proapoptotic intracellular mechanisms induced by a toxic conformer of the recombinant human prion protein fragment 90-231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Approaches to therapy of prion diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Pharmacokinetics of quinacrine in the treatment of prion disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12640-010-9189-8

Differential inhibition of prion propagation by enantiomers of quinacrine

21 January 2018

1 reference

12 December 2020

Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation

1 reference

12 December 2020

Thiolupinine and some derivatives of pharmacological interest.

1 reference

12 December 2020

Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic

1 reference

12 December 2020

Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90-231, as possible mechanism of its neurotoxic effects

1 reference

12 December 2020

Preparation and antileukemic activity of quinolizidinylalkyl-derivatives of 4-aminoquinoline and 9-aminoacridine

1 reference

12 December 2020

Quinacrine in the treatment of refractory petit-mal epilepsy

1 reference

12 December 2020

[Quinolizidine derivatives with antimicrobial activity]

1 reference

12 December 2020

beta 25-35 alters calcium homeostasis and induces neurotoxicity in cerebellar granule cells

1 reference

12 December 2020

Conformation dependent pro-apoptotic activity of the recombinant human prion protein fragment 90-231.

1 reference

12 December 2020

Different structural stability and toxicity of PrP(ARR) and PrP(ARQ) sheep prion protein variants

1 reference

12 December 2020

Neurotoxicity but not infectivity of prion proteins can be induced reversibly in vitro.

1 reference

12 December 2020

Differential effects of staurosporine and retinoic acid on the vulnerability of the SH-SY5Y neuroblastoma cells: involvement of bcl-2 and p53 proteins

1 reference

12 December 2020

Congo red prolongs the incubation period in scrapie-infected hamsters.

1 reference

12 December 2020

Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure-activity relationships

1 reference

12 December 2020

ERK1/2 and p38 MAP kinases control prion protein fragment 90-231-induced astrocyte proliferation and microglia activation

1 reference

12 December 2020

Substituted benzamides with conformationally restricted side chains. 1. Quinolizidine derivatives as selective gastric prokinetic agents

1 reference

12 December 2020

10.1007/S12640-010-9189-8

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1045461279

0 references

1 reference